A lot of optimism and promise surrounds the use of induced pluripotent stem cells (iPSCs) for a number of drug discovery and development applications. Human-derived iPSCs are thought to be more physiologically relevant and better suited for modeling disease pathophysiology and for understanding a drug’s mechanism of action. Hence, cell-based in vitro screening using iPSCs is gaining recognition as a tool for disease modeling, predicting drug efficacy, and toxicology testing. However, technical challenges exist in culturing, differentiating, and characterizing these cells, and skeptics remain unconvinced about the validity of the results obtained.

Panelists:
Dr. Kenneth S. Zaret - Perelman School of Medicine, University of Pennsylvania
Dr. Lior Gepstein - Technion Faculty of Medicine
Dr. Steven A. Goldman - University of Rochester Medical Center

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…